Galderma reports 3-year Nemluvio efficacy data in AD and PN

Galderma says its ARCADIA LTE data show sustained improvements with Nemluvio through Week 152 in adults/adolescents with atopic dermatitis and prurigo nodularis, with no new safety signals reported.